Meadowhawk has deep experience and expertise in non-regulated liquid chromatography mass spectrometry (LCMS) bioanalysis. Taking a two pronged approach, we use diagnostic probes and a 3-tier assay design to analyze different drug modalities in biofluids as well as a variety of tissues from rodent to human.
Whether quantifying small organic molecules or more complex molecule types such as peptides, proteins, nucleotides, lipid nanoparticles and payload of ADCs, our fit-for-purpose model gives you the data you need, when you need it.
Our fit-for-purpose model gives you the data you need, when you need it.
Talk to a ScientistClient dedicated, senior scientific team supported by state-of-the-art instruments
Three fit-for-purpose assay tier levels including screening, lead optimization and IND-enabled
Specialized instruments and diagnostic tools providing critical discovery study data quality insights
A wide range of drug modalities from conventional small organic molecules to complex ADCs
Local courier service to simplify logistics and facilitate the fastest study starts in the area.
With decades of LCMS experience, our scientists serve as your dedicated, single point of contact keeping studies on schedule & facilitating effective communication. Our fit-for-purpose approach provides flexibility to meet discovery stage requests across drug modalities and endogenous biomarkers. Using a 3-tier approach, we serve a full range of bioanalysis (BA) needs including screening, optimization and IND-enabling. In addition, we also support biodistribution requests using matrix matching and surrogate matrix approaches.
To expedite compound and sample logistics, we provide local courier service that often picks up within 24 hours of your request.
Accurately assessing the characteristics and behavior of new compounds during drug discovery can be challenging but is crucial to ensuring stability, efficacy, and safety. Learn how Meadowhawk helps researchers make quicker, cost-effective decisions.
Accurately assessing the biodistribution and pharmacokinetics of candidate therapeutic compounds during drug discovery can...
Read